Relief Therapeutics reports promising preliminary results for EB treatment RLF-TD011, reducing harmful bacteria and improving wound healing.

Relief Therapeutics Holding SA has reported promising preliminary results from a clinical trial of RLF-TD011, targeting epidermolysis bullosa (EB), a rare genetic skin disorder. The treatment showed significant reductions in Staphylococcus aureus, a harmful bacteria in EB wounds, while enhancing beneficial bacteria and improving wound healing. The FDA has granted RLF-TD011 orphan drug designation, and the company plans to pursue additional market exclusivity designations.

October 08, 2024
7 Articles

Further Reading